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The widely different LC-MS response observed for many structurally different compounds
limits the use of LC-MS in full scan detection mode for quantitative determination of drugs
and metabolites without using reference standard. The recently introduced nanospray
ionization (NSI) technique shows comparable MS response for some compounds under
non-LC-MS conditions. However, in the presence of numerous endogenous compounds
commonly associated with biological samples such as urine, plasma, and bile, LC-MS is
required to separate, detect, identify, and measure individual analytes. An LC-NSI-MS system
was devised and the MS response obtained in this system for a variety of pharmaceutical drugs
and their metabolites. The set-up involves two high-performance liquid chromatography
(HPLC) systems, a chip-based NSI source and a quadrupole-time-of-flight (Q-TOF) mass
spectrometer. Herein this is referred to as the response normalized-liquid chromatography
NSI-MS (RNLC-NSI-MS) system. One HPLC unit performs the analytical separation, while the
other unit adds solvent post-column with an exact reverse of the mobile phase composition
such that the final composition entering the NSI source is isocratic throughout the entire HPLC
run. The data obtained from four different structural classes of compounds [vicriviroc (VCV),
desloratadine (DL), tolbutamide, and cocaine] and their metabolites indicate that by maintain-
ing the solvent composition unchanged across the HPLC run, the influence of the solvent
environment on the ionization efficiency is minimized. In comparison to responses obtained
from radiochromatograms, responses from conventional LC-ESI-MS overestimated the VCV
and DL responses, respectively, by 6- and 20-fold. Although VCV and DL responses obtained
using LC-NSI-MS are within 2- to 6-fold from the respective radiochromatographic responses,
the response normalization modification results in nearly uniform LC-NSI-MS response for all
compounds evaluated. (J Am Soc Mass Spectrom 2007, 18, 1891–1899) © 2007 American
Society for Mass SpectrometryLiquid chromatography-mass spectrometry (LC-MS) with atmospheric pressure ionization (API)has become the preferred tool in the pharmaceu-
tical industry for qualitative and quantitative determi-
nation of drugs and their metabolites in biological
matrices. The widely different LC-MS responses ob-
served for compounds with structural changes, such as
those resulting from metabolism, however, limits the
use of LC-MS in full scan detection mode for quantita-
tive determination of drugs and/or metabolites. LC-
MS/MS based assays involving selected reaction mon-
itoring (SRM) or multiple reaction monitoring (MRM)
techniques are routinely used for quantitative determi-
nation of drugs and/or metabolites in biological matri-
ces [1–7]. LC-MS/MS techniques for quantitation re-
quire reference and internal standard(s), so that LC-
MS/MS responses from unknown quantities of relevant
drug-related peaks can be related back to responses
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ally a standard curve is generated for each and every
analyte to be quantified [6]. Although reference stan-
dards may be available for the parent drug, it is very
unlikely to have standards for metabolites available in
early stage of drug discovery and development thereby
making conventional LC-MS/MS based quantitation of
metabolites impractical.
Nanospray ionization (NSI), introduced by Wilm
and Mann in the 1990s [8], has been used to identify
proteins [9 –13] and drug metabolites [14], quantify
pharmaceutical drugs [15, 16], study absorption, distri-
bution, metabolism and excretion (ADME) properties of
drugs [17], and employed in various other applica-
tions [12, 13, 15, 16, 18–34]. NSI-MS has the following
advantages over conventional flow ESI-MS: (1) higher
sensitivity, (2) lower rate of sample consumption, and
(3) improved signal-to-noise ratio (S/N). Although both
on- and off-line NSI-MS have been developed, off-line
NSI-MS methods have been more frequently used be-
cause of the technical difficulties associated with inter-
facing conventional flow LC systems with NSI and
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MS/MS experiments on a given LC time scale. Further-
more, the flow rate at which a compound is introduced
into the mass spectrometer influences ionization effi-
ciency and therefore variability in LC-MS response
[35-37].
Recently, using a silicon microchip, Hop et al. [36]
and a custom-built pulled capillary, Valaskovic et al.
[29], studied the NSI-MS response of different classes of
drugs and their metabolites by infusing directly into the
NSI-MS system. Hop et al. [36] compared ionization
efficiencies of drugs and metabolites in conventional
flow (500-L/min) LC-MS using electrospray ioniza-
tion with that in a microchip based infusion NSI-MS
and showed that in the latter technique the ionization
efficiencies vary to a much lesser extent. Valaskovic et
al. [29] demonstrated that as the flow rate in nanospray
is reduced, the differences in ionization efficiencies
among various compounds also reduce and at a flow
rate of about 10 nL/min most compounds show similar
ionization efficiency.
These encouraging results were obtained by direct
infusion of analytes into NSI-MS systems. However,
analysis of drugs and metabolites are usually per-
formed from biological matrices or extracts. Metabo-
lites, which are likely to be isobaric (same modification
at different sites) and accompanied by endogenous
salts, fatty acids, peptides, and proteins require chro-
matographic separation before analysis. Therefore, an
NSI-MS system coupled to a HPLC is the most desirable
approach for metabolite characterization.
In this paper, results from an investigation of an
on-line LC-NSI-MS system and the role of mobile phase
composition on the variation of ionization efficiencies of
different classes of drugs [vicriviroc (VCV), deslorata-
dine (DL, Clarinex), tolbutamide (TOL) and cocaine],
and their metabolites are described. The analysis of a
series of DL- and VCV-related compounds were per-
formed directly from urine. These data were further
compared with those from conventional LC-MS with
electrospray ionization using the same gradient for
separation.
Experimental
Materials
HPLC grade acetonitrile and methanol were from Bur-
dick and Jackson (Muskegon, MI). Water was purified
using the Millipore Milli-Qplus water purification sys-
tem (Bedford, MA). Acetic acid and ammonium acetate
were from Sigma-Aldrich (St. Louis, MO). Cocaine and
benzoylecgonine were obtained from Cerilliant Corpo-
ration (Round Rock, TX) as 1 mg/mL free base in
acetonitrile and methanol, respectively. Solutions were
further diluted in 1:1 mixture of methanol:acetonitrile to
a final solution containing 20 M each cocaine and
benzoylecgonine. Tolbutamide (TOL) and hydroxytol-
butamide (OH-TOL) were purchased from Sigma-Al-drich as powders, dissolved and diluted in methanol to
a final concentration of 20 M. All other reagents and
solvents were obtained from commercial sources. A 25
L aliquot of the standard mixture was injected for all
LC-MS experiments.
Capsules containing 14C-VCV {1-[[(4,6-dimethyl-5-
pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-(4-triflu-
oromethyl)phenyl]ethyl]-3(S)-methyl-1-piperazinyl]-4-
methylpiperidine, 14C-SCH 417690} were formulated,
manufactured and released at the Schering-Plough Re-
search Institute (Kenilworth, NJ). As detailed elsewhere
[38-41], urine was collected in block intervals for 10 d
following a single 50 mg administration of 14C-VCV
(100 Ci) to six healthy volunteers. This was a Phase I
open-label study designed to characterize the absorp-
tion, metabolism, and excretion of 14C-VCV. Following
centrifugation, a 100 to 150 L aliquot of urine (0 to 6 h)
from a single subject was injected for all LC-MS exper-
iments. The radioactivity content in the urine was about
60 DPM/L.
14C-DL [8-chloro-6, 11-dihydro-11-(4-piperidyli-
dene)-5H-benzo [5,6] cyclohepta [1,2-b]pyridine, 14C-
SCH 34117] was synthesized at Schering-Plough Re-
search Institute (Kenilworth, NJ) and had 99%
radiochemical purity. As described elsewhere [42, 43],
monkeys (n 3) were administered a single oral dose in
0.4% aqueous methylcellulose by gavage at a targeted
dose level of 6.5 mg [14C]DL/kg (80 Ci/kg). Urine was
collected at selected intervals through 240 h post-dose.
Urine samples were pooled by taking 10% to 25% of the
volume collected over each time interval. Equal vol-
umes from each individual pool were mixed together to
obtain a pooled 0 to 24 h composite urine. Following
centrifugation, a 100-L aliquot of the pooled compos-
ite urine sample was injected for LC-MS analysis with
in-line radioactivity detection (FSA). The radioactivity
content of the urine was about 500 DPM/L.
LC-ESI-MS
All LC-ESI-MS experiments were performed using a
TSQ Quantum mass spectrometer (Thermo Electron
Corp., San Jose, CA) equipped with a vendor supplied
source operated in the positive ionization mode. ESI
source and MS conditions were optimized using reser-
pine (10 ng/L) to avoid preferential MS conditions for
any one of the metabolites or drugs. The mass spec-
trometer was nominally operated with the spray needle
voltage, capillary offset and capillary temperature set at
4.0 kV, 35 V, and 300 °C, respectively. For all LC-MS
experiments, the Q1 resolution (FWHM, full width at
half-maximum) and the first/last mass were set at 0.7
Th and 100/1100 Da, respectively.
A Waters Alliance HPLC system (Alliance Model
2690; Waters Corp., Milford, MA) and a 4.6 mm  250
mm Luna Phenyl-Hexyl column (Phenomenex, Tor-
rance, CA) were used for all LC separations. The
column was maintained at room temperature. The
mobile phase, 95% 10 mM ammonium acetate with 5%
1893J Am Soc Mass Spectrom 2007, 18, 1891–1899 RESPONSE NORMALIZED MASS SPECTROMETRYacetonitrile, adjusted to pH 6.0 with acetic acid (A) and
95% acetonitrile with 5% water (B), was delivered at a
constant flow rate (1 mL/min). The linear gradients
used in this investigation are shown in Table 1.
For all experiments involving radioactive samples,
15% of the column effluent was utilized for LC-ESI-MS
experiment while 85% of the column effluent was
diverted to a Model 500TR (Packard Instrument Co.,
Meriden, CT) flow scintillation analyzer (FSA)
equipped with a 250-L liquid flow cell (Packard In-
strument Co., Meriden, CT). Flo-Scint III cocktail (Pack-
ard Instrument Co., Meridian, CT) was used as scintil-
lation fluid at a flow rate of 2.4 mL/min. FSA was
controlled by FLO-ONE for Windows software (version
3.65, Packard Instrument Co., Meriden, CT). All radio-
activity data were processed and integrated using the
same software. This simultaneous detection of all drug-
derived material by an MS and an FSA provided
confirmation of the molecular weight of all radioactive
peaks in a simple LC-MS experiment. For all non-
radioactive samples, 15% of the flow was diverted to
the mass spectrometer and the remainder to waste.
Following LC-MS/FSA analysis, the area of each
detected radioactive peak in the FSA was expressed as
a percent of peak area of the most abundant peak (set to
100%) in the radiochromatogram. Similarly, from
LC-MS spectra, peak areas of the metabolites and the
corresponding parent drug were integrated using Xcali-
bur software (ThermoFinnigan, San Jose, CA) and then
normalized to the peak area of the most abundant peak.
For comparison the integrated peak areas of metabolites
and the parent drug from radiochromatograms (only
for VCV and DL) and LC-MS spectra were plotted using
Excel (Microsoft Corporation, Red Bank, WA) to gener-
ate bar graphs.
Nanoelectrospray Ionization (NSI) Source
All LC-NSI experiments were performed using an au-
tomated chip-based Triversa NanoMate (Advion Bio-
Sciences, Ithaca, NY) source operated by ChipSoft soft-
ware operating under Windows XP. The Triversa
NanoMate source provided options to perform: (1)
Table 1. Linear LC-MS gradients used in this study
VCV and DL
Experiments
Tolbutamide
Experiments
Cocaine
Experiments
Time
(min) %A %B
Time
(min) %A %B
Time
(min) %A %B
0 90 10 0 98 2 0 98 2
10 70 30 15 10 90 20 10 90
40 30 70 15.1 98 2 20.1 98 2
40.1 10 90 20 98 2 25 98 2
50 10 90
50.1 90 10
60 90 10infusion from a 96-well sample plate using a rack of96-disposable conductive pipette tips connected to a
robotic mandrill, (2) on-line fraction collection into
96-well plate during LC-MS experiments, and (3)
LC-MS experiments using a conductive re-usable pi-
pette tip based LC coupler. All experiments described
in this paper used a silicon wafer based microchip
consisting of a 20  20 array of non-reusable nozzles
fabricated by proprietary etching techniques. Each noz-
zle had an i.d. of 5.5 m and the nozzle design allowed
flow rates between 200 and 500 nL/min. For optimal
performance, the microchip was positioned about 4.5
mm from the sampling cone of a quadrupole time-of-
flight (Q-TOF Global) mass spectrometer (Waters Cor-
poration, Beverly, MA). To improve the nozzle-to-
nozzle reproducibility and to maintain continuous
spray during an LC run, the ChipSoft software moni-
tored the ion current. When the ion current fell below 20
nA or went over 400 nA, the spray was automatically
switched over to the next nozzle.
LC-NSI-MS
All LC-NSI-MS analyses were performed using a Q-
TOF Global (Waters Corporation) mass spectrometer
equipped with an automated chip based Triversa Nano-
Mate NSI source described above. All MS conditions
and NSI source orientations were optimized by infusing
reserpine. Typical NanoMate infusion conditions are
described elsewhere [15]. For all LC-NSI-MS experi-
ments, the Q-TOF mass spectrometer was operated as
follows: ionization mode, positive; spray voltage, 1.7 to
1.9 kV; cone voltage, 45 V; source temperature, 45 °C;
collision gas, 1.5 mTorr; scan range, 100 to 1100; inter-
scan time, 0.1 s. Data for each sample was acquired over
the entire LC run time in the profile mode with mass
resolution for reserpine set at 8000 (full width at half
maximum).
Chromatographic separations in LC-NSI-MS experi-
ments were achieved using the same linear gradients,
mobile phases and analytical column (4.6 mm  250
mm Luna Phenyl-Hexyl; Phenomenex, Torrance, CA)
used for LC-ESI-MS. The HPLC unit consists of Shi-
madzu LC-10AD vp pumps and a SIL-10AD vp au-
tosampler (Shimadzu Corporation, Kyoto, Japan). This
system is hereafter termed the “analytical HPLC” sys-
tem. For all LC-NSI-MS experiments (Figure 1), the
column effluent was split such that most (85%) of the
effluent was directed into the FSA (for VCV and DL
experiments) or to waste and the remainder (15%)
diverted to the TriVersa NanoMate NSI source. Within
the TriVersa NanoMate, the HPLC flow (15% or 150
L/min) was further split to deliver about 200 to 500
nL/min to the NanoMate chip via the LC coupling
device and the rest to NanoMate fraction collector or
waste. All split ratios were adjusted by varying ID and
lengths of PEEK tubing (all connections exterior to
NanoMate) and fused silica capillary (all connections
within the NanoMate). Split ratios were verified by
injecting radioactive samples, collecting effluent, and
-NSI
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try (LSS). All LC-MS data were processed and inte-
grated using the MassLynx software.
RNLC-NSI-MS
The response normalized liquid chromatography
(RNLC)-NSI-MS (Figure 1) experiments utilized two
HPLC systems: an “analytical HPLC” and a “response
normalizing (RN) HPLC”. The RN-HPLC is used to
deliver mobile phase post column with a gradient
program exactly reversed from that used for analytical
separation [37]. A Waters Alliance HPLC system (Alli-
ance Model 2690; Waters Corp., Milford, MA) was used
as the RN-HPLC. The flow rate of the RN-HPLC system
was varied between 50 L/min to 250 L/min and
optimized using an equimolar mixture of TOL and
OH-TOL. RN-HPLC flow was optimized at 0.15 mL/
min. The presplit flow rate of the “analytical LC”
system was 1.0 mL/min.
Results and Discussion
The response of different analytes under LC-MS condi-
tions was investigated for both higher flow rate (150
L/min) ESI-MS and lower flow rate (200 to 500
nL/min) NSI-MS using DL, VCV, and their respective
Autosampler
Analytic
HPLC
al
Column
Guard Column
~0.1 – 0.3 mL/min
~ 0.7-0.9 mL/min
1.0 mL/min
To 14C-detector
or any
other detector
Pump A: Aqueous
Mobile Phase
Pump B: Organic
Mobile Phase
Mixing Tee-1 (T-1) Mixing Tee-2 (
Nanoma
Inline Check Valve
Figure 1. A schematic of the experimental set-
nanospray ionization mass spectrometry (RNLCmetabolites. The amounts of material injected in thefour experiments reported here are provided in Table 2.
The ionization efficiency in LC-NSI-MS was further
investigated by reducing the variability in solvent com-
position that occurs during a gradient analysis by
adding a solvent mixture post-column with an exact
reverse gradient to that used for analytical separation.
The latter procedure is referred hereafter as RNLC-NSI-
MS.
The first set of experiments involved LC-MS of urine
collected following administration of 50 mg 14C-VCV to
healthy male volunteers. A comparison of LC-MS re-
sponses of VCV and its metabolites (M2/M3, M15, M35,
and M41) (Figure 2) obtained using ESI and NSI as
ionization modes with and without RN flow along with
the corresponding radioactivity (LC-FSA) data is shown
in Figure 3. All LC-MS and LC-FSA data (peak areas)
are an average of three separate analyses and the
200-500 nL/min
MS
~0.2 – 0.6 mL/min
To fraction
collector
or to waste
TriVersa Nanomate
or any other nanoflow
electrospray ionization
source
ESI chip whe
Nanomate
n using
esponse
ormalizing HPLC
Pump A: Organic
Mobile Phase
Pump B: Aqueous
Mobile Phase
Guard Column
0.1 – 0.3 mL/min
Make-up flow arrangement
for normalization of
trospray
s spectrometry
responses
nanoflow elec
ionization mas
lkhead
r response normalized liquid chromatography
-MS).
Table 2. The amounts of material injected
Sample
Volume
injected
Amount on
column
Tolbutamide and
hydroxytolbutamide
25 L 125 g each
Cocaine and
benzoylecgonine
25 L 125 g each
14C-VCV derived radioactivity 150 L 1.9 g total
14R
N
~
T-2)
te Bu
up foC-DL derived radioactivity 50 L 1.6 g total
aboli
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peak. M35 or VCV-O-desmethyl-glucuronide was the
major human urinary metabolite and therefore MS
responses of all other drug-derived analytes were nor-
malized to this compound to facilitate a comparison.
LC-FSA detection is nondiscriminating with respect to
Figure 3. Comparison of LC-MS responses ob
NSI-MS, and radioactivity detection for vicriviro
to the major metabolite (M35)]
F
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Figure 2. Structures of Vicriviroc and its metmolecular weight, chemical structure and is relativelyimmune to most matrix effects. As demonstrated in
Figure 3, the LC-ESI-MS detector signal differed much
more widely for VCV and its metabolites in comparison
to those obtained using a radioactivity detector (FSA).
Had this study been conducted using non-radiolabeled
drug and only the LC-ESI-MS response used (without
d using conventional flow LC-ESI-MS, RNLC-
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unchanged drug (VCV) would have been grossly overes-
timated (identified as the major urinary drug-related ma-
terial). Similarly, the relative amounts of all metabolites
would have been underestimated. With M35 the major
metabolite underestimated by a factor of six.
The MS response obtained in the LC-NSI-MS for the
same urine sample shows a marked contrast to those
data obtained using LC-ESI-MS (Figure 3). Without any
RN flow in LC-NSI-MS, M35 is the most abundant
drug-related material as shown by radioactivity traces.
The responses for M41, M2/M3, and VCV decreased
relative to M35, although, M2/M3 and VCV would still
have been overestimated by a factor of 2 to 3. The
differences in the NSI-MS response of various com-
pounds in LC-NSI-MS were further reduced when
response normalizing (RN) flow was added. The LC-
NSI-MS responses of VCV and metabolites with RN
flow rates of 0.15 and 0.2 mL/min are comparable to
N
Cl
N
H
([M + H]+ @ m/z 311)
Desloratadine (DL, Clarinex)
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M9 (6-OH-DL-glucuronide)
Figure 4. Structures of desloratadine and its metabolites that
were evaluated using NRLC-NSI-MS.
Table 3. Comparison of peak area normalized data for conventi
and its metabolites
Drug/metabolites
(mass-to-charge ratio) Radioactivity
Withou
normalizi
HPLC flo
DL (m/z 311) 2.63 61.5
M31&M33 (m/z 327) 37.0 378
M9 (m/z 503) 100 100
M7 (m/z 503) 38.2 23.9those obtained on an LC-FSA system. Additional exper-
iments employing 0.16 and 0.18 mL/min RN flow rates
did not bring the LC-NSI-MS responses any closer to
the radioactivity data. Therefore, the RN flow rate was
close to optimal at about 0.15 mL/min. This could be
potentially due to the similarity between the RN flow
and the flow reaching the NSI source as described in the
experimental section, resulting in an isocratic final
solvent composition (50:50  aqueous:organic) reach-
ing the NSI source throughout the LC run in this
RNLC-NSI-MS experiment.
While LC-FSA responses showed that M15 was at
about 25% of M35, RN normalized LC-NSI-MS responses
showed M15 to be about 15% of M35. This discrepancy
was carefully evaluated and later attributed to a metabo-
lite at an m/z 494 co-eluting with M15. The contribution of
this metabolite was inseparable in the radioactivity peak
but did not contribute to the NSI response of M15.
The second set of experiments involved pooled (n 3)
0 to 24 h urine collected following oral administration of
8 mg 14C-DL/kg to male monkeys (Figure 4). In addition
to obtaining radiochromatograms using LC-FSA, LC-MS
analysis was performed in four different modes: LC-ESI-
MS, RNLC-ESI-MS, LC-NSI-MS, and RNLC-NSI-MS. The
data from these four experiments and from LC-FSA are
provided in Table 3. A comparison of the responses of DL
and its metabolites in five different detection/analysis
modes showed that under conventional flow LC-ESI-MS
conditions, the levels of DL and M31/M33 are overesti-
mated by about twenty and ten times, respectively when
compared to the radioactivity responses. The responses in
LC-NSI-MS without RN normalization are much closer to
the data obtained using LC-FSA (Table 3). The addition of
the RN flow brought down the response of DL closer to
the radioactivity value, however, the responses for M31/
M33 were reduced. In LC-NSI-MS with and without RN
flow, the response for M7 was underestimated. This was
again attributed to two other co-eluting metabolites con-
tributing to LC-FSA integrated peak area for M7. Because
of the m/z difference, these metabolites did not contribute
to the XIC peak area for M7. It should be noted that the
RN flow addition had no effect on the MS response of DL
and metabolites in the conventional flow LC-ESI-MS.
As a further demonstration of the potential for
response normalization in LC-NSI-MS, the NSI-MS re-
sponses of equimolar mixtures (20 M each, 25 L
flow LC-ESI-MS and nano flow LC-ESI-MS for desloratadine
-ESI-MS LC-NSI-MS
0.15 mL/min
normalizing
HPLC flow
Without
normalizing
HPLC flow
0.15 mL/min
normalizing
HPLC flow
50.8 5.0 2.52
371.2 33.1 26.6
100 100.0 100onal
LC
t
ng
w23.4 13.4 14.8
ng (R
1897J Am Soc Mass Spectrom 2007, 18, 1891–1899 RESPONSE NORMALIZED MASS SPECTROMETRYinjected) of tolbutamide (TOL), hydroxyl-tolbutamide
(OH-TOL), cocaine, and benzoylecgonine were exam-
ined. As shown in Figure 5, without the use of RN flow,
the LC-NSI-MS response (peak area) of equimolar mix-
tures of TOL and OH-TOL were 25 and 8, respectively
(Figure 5). With the addition of RN flow (0.15 mL/min),
equal LC-MS responses were obtained. This experiment
was repeated 15 times within a span of 6 mo and with
0.15 mL/min RN flow rate, the response of OH-TOL
was within 95% to 105% of the LC-NSI-MS response of
TOL. Under LC-ESI-MS conditions, the XIC response of
OH-TOL was in the range of 25% to 28% of TOL from
an equimolar mixture of TOL and OH-TOL. The ESI-MS
data are comparable to the results reported by Valask-
ovic et al. [29]. In an attempt to achieve MS response
comparable to the concentrations of analytes, Valask-
ovic et al. [29] reduced the NSI flow rate to 7 nL/min.
Even at 7 nL/min, the response ratio for TOL:OH-TOL
was 1:0.8. With the use of RN flow on a chip-based
nanospray system (Nanomate), a response ratio of 1:0.9
or better was routinely achieved for equimolar mixture
of TOL and OH-TOL.
A similar set of experiments was performed using an
equimolar mixture of cocaine and benzoylecgonine.
Again, RNLC flow helped to achieve near equal LC-
NSI-MS responses. Without the RN flow, the LC-
NSI-MS response of cocaine was almost three times
higher than that for benzoylecgonine; however, nearly
equal responses were obtained following the addition
of RN flow (Figure 6). The response normalized ratio
ranged from 1:0.85 to 1:1.2. By reducing the NSI flow
rate to 3.7 nL/min, Valaskovic et al. [29] achieved an
MS response ratio of only 1:0.5 for an equimolar mix-
ture of cocaine and benzoylecgonine.
Although RNLC-NSI-MS provides an improvement in
2.50 5.00 7.50 1
0
100
%
0
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%
I6082504 Sm (Mn, 2x5)
4
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8
CH3
S
N
H
N
H
CH3
OOO
OH
Hydroxy-tolbutamide (OH-TOL, [M+H]+ at m/z
Response Normalizing HPLC 
Flow at 0.15 mL/min
Without Response Normalizing HPLC
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Tim
Figure 5. LC-MS chromatograms of tolbutamid
and without (bottom panel) response normalizinormalization ofMS response in LC-NSI-MS, therewas anoverall reduction of the sensitivity of analyte responses
following the addition of RN flow. The reduction in ion
intensities can be attributed to two factors. First, the
addition of RN flow reduces the analyte concentration by
a factor of two. Second, response normalization maintains
a constant mobile phase composition (50:50 organic: aque-
ous) throughout the LC run. Therefore, the responses of
those analytes that elute at 50% organic content of the
mobile phase are reduced in RNLC-NSI-MS. Nonetheless,
the data presented here demonstrates that the sensitivity
in RNLC-NSI-MS is suitable for characterization and esti-
mation of drugs and metabolites directly from biological
matrices.
The results presented here are encouraging and
indicate that the RN flow addition reduces the variabil-
ity in NSI-MS response due to differences in the mobile
phase composition in a gradient LC experiment. A
variety of different compounds yielded relative NSI-MS
response comparable to their concentration in biological
matrices concurrently established using radiometric de-
tection. These data suggest that RNLC-NSI-MS can be
used to simultaneously acquire semiquantitative infor-
mation during structural characterization of drugs and
metabolites. Results reported here indicate that metab-
olite levels can be estimated from studies conducted
with non-radiolabeled drugs in early exploratory drug
metabolism and clinical programs.
Conclusions
The addition of response normalization flow to the LC
effluent in LC-NSI-MS minimizes the effect on the analyte
response resulting from changes in the solvent composi-
tion in gradient elution experiments. Response normaliza-
tion results in similar MS responses for all analytes in a
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271+287
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271+287
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n)
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N) HPLC flow.0.00
287)
e (mi
e andrelated series. Therefore, RNLC-NSI-MS can be used to
N) H
1898 RAMANATHAN ET AL. J Am Soc Mass Spectrom 2007, 18, 1891–1899improve quantitative estimates for metabolite levels in
exploratory and early clinical drug metabolism studies
when radiolabeled drugs are typically not available or
when impractical to administer to humans. Other appli-
cations may include determination of impurity levels in
drug substance/products from manufacturing processes
and reaction byproducts during chemical synthesis.
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